Floatz logo

Adapt-001

Chondrosarcoma

EpicentRx, Inc.UNKNOWNPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Chondrosarcoma cohort.

Asset / SponsorPhaseRating
Ivosidenib
Memorial Sloan Kettering Cancer Center
Phase 2B
Cis-Diamminedichloroplatinum Ii
Eli Lilly and Company
Phase 1/2CCC
Azacitidine
IGM Biosciences, Inc.
Phase 1/2CCC
Talfirastide
Wake Forest University Health Sciences
Phase 2CCC
Atezolizumab
National Cancer Institute (NCI)
Phase 2CCC

View all 22 →

Same molecule, other indications

Adapt-001 is also rated in:

soft tissue sarcomaActive
CCC
Indicative · Phase 2
53 / 100
View asset →
sarcomaActive
CCC
Indicative · Phase 2
51 / 100
View asset →
cancerActive
CCC
Indicative · Phase 2
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →